Drug profile · INN
catumaxomab
KORJUNY
catumaxomab (KORJUNY) is a epithelial cell adhesion molecule cross-linking agent.
Drug details — catumaxomab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 4
- Programs
- 0
- Data quality
- 0.83
Quick answer
catumaxomab (KORJUNY) is a epithelial cell adhesion molecule cross-linking agent.
Key facts
Mechanism of action
Epithelial cell adhesion molecule cross-linking agent
Primary target: Epithelial cell adhesion molecule
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Related patents
-
US 8541482
Removable multilayer nail coating system and methods therefore
granted -
US 8492454
Removable color layer for artificial nail coatings and methods therefore
granted -
US 8367742
Removable color layer for artificial nail coatings and methods therefore
granted -
US 8263677
Removable color gel basecoat for artificial nail coatings and methods therefore
granted
Frequently asked questions
What is catumaxomab?
catumaxomab (KORJUNY) is a epithelial cell adhesion molecule cross-linking agent.
What is the brand name for catumaxomab?
KORJUNY is a marketed brand name for catumaxomab. Check FDA Drugs@FDA for the current US label holder and prescribing information.